Neuroinflammation in Alzheimer's disease – PubMed

Competing interests: AJT serves on the scientific advisory board and/or consultant for Alnylam, Apellis, Montis, and has a research contract with Visterra. C. Cruchaga has received research support from GSK and EISAI. C. Cruchaga is a member of the scientific advisory board and owns stock in Circular Genomics. C. Cruchaga is a member of Admit's Scientific Advisory Board. DJB has a financial interest in this research. He is a co-inventor on patents held by Mayo Clinic, patent applications licensed to or filed with Unity Biotechnology, and a stockholder in Unity Biotechnology. Research at the Baker Institute has been reviewed by Mayo Clinic's Conflict of Interest Review Committee and is conducted in accordance with Mayo Clinic's Conflict of Interest Policy. DM serves on the advisory boards of Mindimmune, InMed, and SynapsDx. He works with Hesperos Inc. C. Cunningham serves on the advisory board of Exalys Therapeutics and has received small research grants from IONIS Therapeutics. CT works with Acumen, ADx Neurosciences, AC-Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, Cognition Therapeutics, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant Nano Biosensors We have a contract. , Novo Nordisk, Orlink, PeopleBio, Quanterix, Roche, Toyama, and Vivolillon. She is Editor-in-Chief of Alzheimer Research and Therapy and serves on the editorial boards of Molecular Neurodegeneration, Neurology: Neuroimmunology and Neuroinflammation, and Medicact Neurology Springer. He also serves on committees that define guidelines for acute neurology. She has had consultant/speaker agreements with Aribio, Biogen, Beckman-Coulter, Cognition Therapeutics, Eli Lilly, Merck, Novo Nordisk, Olink, Roche, and Veravas. DB has served as a consultant to Biogen. DRT collaborated with Novartis Pharma AG (Switzerland) and GE-Healthcare (UK). GD holds two patents for immunomodulatory treatments for Alzheimer's disease and tauopathies, serves on the scientific advisory board of Coya Therapeutics, and receives faculty fees from Eisai and research support from Institut Roche. HZ has served on scientific advisory boards and as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, and Nervgen. Ta. , Novo Nordisk, Optoceutics, Passage Bio, Pintheon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, Wave, Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk He has given talks sponsored by , Roche, and WebMD. Co-founder of Brain Biomark Solutions in Gothenburg AB (BBS). Part of the GU Ventures Incubator Program (externally submitted work). KA is a co-founder of Willow Neuroscience, Inc. and a member of SAB. LA serves as a consultant to Intelgenx. MC is a member of the scientific advisory boards of Vigil, NGMBio, Cell Signaling Technology, Cartesian, and Halyard. Received research support from Ono Pharmaceutical Co., Ltd. Patents are pending for LILRB4 and TREM2. OB is a co-founder and a member of the scientific advisory boards of Glial Therapeutics and GliaX. OB collaborates with GSK and Regulus Therapeutics and has received research funding from Sanofi, GSK, speaking fees, and consultants from UCB, Camp4, Ono Pharma USA, and General Biophysics. R. Mancuso has or is conducting scientific collaborations with Alector, Nodthera, Alchemab, Roche and is a consultant to Sanofi. RR is a full-time employee of Third Rock Ventures, a company building new biotechnology companies with interests in neurodegeneration. He is also a co-founder and holds an equity stake in Abashi Therapeutics. SAL maintains financial interests in AstronautTx Ltd. and Synapticure and participates in SAB of the Global BioAccess Fund. SH has received lecture fees from Eisai Co., Ltd., Novo Nordisk, and Alnylam, research funding from Eisai Co., Ltd., and has joint projects with Ionis Co., Ltd. WMvdF. With funding from ZonMW, NWO, EU-JPND, EU-IHI, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health Holland, Topsector Life Sciences & Health, stichting Dioraphte, Gieskes-Strijbis von, stichting Equilibrio, and Edwin Bouw von. are or are receiving. Passman Stitch, Stitching Alzheimer & Neuropsychiatric Foundation, Philips, Biogen MA Inc., Novartis-NL, Life-MI, AVID, Roche BV, Eli Lilly-NL, Fujifilm, Eisai, Combinostics. WMvdF. He has been an invited speaker at Biogen MA Inc., Danone, Eisai, WebMD Neurology (Medscape), NovoNordisk, Springer Healthcare, and the European Brain Council. Consultant to Oxford Health Policy Forum CIC, Roche, Biogen MA Inc., and Eisai. All funds were paid to her institution. WMvdF. Served on advisory boards for Biogen MA Inc., Roche, and Eli Lilly. WMvdF. I am a member of the steering committee of EVOKE/EVOKE+ (NovoNordisk). All funds were paid to her institution. WMvdF. He is a member of the steering committees of PAVE and Think Brain Health. WMvdF. In 2020/2021, he served as Deputy Editor-in-Chief of Alzheimer's Research & Therapy, and currently serves as Deputy Editor-in-Chief of Brain. PE was funded by the Medical Research Council and is currently funded by the Higher Education Funding Council for England (HEFCE). He has also received grants from Alzheimer's Research UK, Alzheimer's Drug Discovery Foundation, Alzheimer's Society UK, Medical Research Council, Alzheimer's Society USA, Van Geest Foundation, and the European Union. PE is a consultant for Roche, Pfizer and Novo Nordisk. He has received teaching and research grants from GE Healthcare, Novo Nordisk, Piramal Life Science/Life Molecular Imaging, Avid Radiopharmaceuticals, and Eli Lilly. He was a member of Novo Nordisk's Scientific Advisory Board. All other authors have no conflicts of interest to declare.